Soligenix
12
1
1
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
16.7%
2 terminated/withdrawn out of 12 trials
81.8%
-4.7% vs industry average
33%
4 trials in Phase 3/4
78%
7 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light
Role: collaborator
Topical SGX302 for Mild-to-Moderate Psoriasis
Role: lead
Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL
Role: lead
HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL
Role: lead
Dusquetide for the Treatment of Behcet's Disease
Role: lead
PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma
Role: lead
DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer
Role: lead
FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
Role: lead
Study of orBec® as Monotherapy in the Treatment of Patients With Upper GI Symptoms Caused by Chronic Graft Versus Host Disease (GVHD)
Role: lead
A Dose Escalating Study of SGX942 for Oral Mucositis in Patients With Head and Neck Cancer
Role: lead
Study of orBec® With Prednisone Therapy in the Treatment of Patients With Graft Versus Host Disease (GVHD)
Role: lead
A Dose Ranging Study of Delayed Release Beclomethasone for Prevention of Acute Enteritis in Patients With Rectal Cancer
Role: lead
All 12 trials loaded